Cipla USA, Inc, a subsidiary of Cipla, has secured rights from Hyderabad-based MSN Laboratories to market and distribute colon cancer treatment drug Capecitabine in the US market. The company will be marketing the drug in strengths of 150 and 500 mg tablets. Its product is generic equivalent of Genentech's Xeloda.
Capecitabine tablets are indicated in patients with Dukes C colon cancer and for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. As per IQVIA (IMS Health), Xeloda and its generic equivalents had sales of around $178 million in the US for 12-month period ending June 2018.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1904.65 |
| Dr. Reddys Labs. | 1374.55 |
| Cipla | 1458.45 |
| Zydus Lifesciences | 1141.00 |
| Lupin | 2476.10 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: